peregrine_10q-ex10115.htm


    Exhibit 10.115

     

    INTELLECTUAL
PROPERTY SECURITY AGREEMENT

    


    This Intellectual Property Security
Agreement is entered into as of December 19, 2008 by and between MIDCAP FUNDING
I, LLC ("Agent") and PEREGRINE PHARMACEUTICALS, INC.
("Grantor").

    


    RECITALS

    


    A.           The
Lenders have agreed to make certain advances of money and to extend certain
financial accommodation to Grantor (the "Loans") in the amounts and manner set
forth in that certain Loan and Security Agreement by and between Agent, the
Lenders, Avid BioServices, Inc. and Grantor dated the Effective Date (as the
same may be amended, modified or supplemented from time to time, the "Loan
Agreement"; capitalized terms used herein are used as defined in the Loan
Agreement).  The Lenders are willing to make the Loans to Grantor, but
only upon the condition, among others, that Grantor shall grant to Agent, for
the ratable benefit of the Lenders, a security interest in certain Copyrights,
Trademarks, Patents, and Mask Works (as each term is described below) to secure
the obligations of Grantor under the Loan Agreement.

    


    B.           Pursuant
to the terms of the Loan Agreement, Grantor has granted to Agent, for the
ratable benefit of the Lenders, a security interest in all of Grantor's right,
title and interest, whether presently existing or hereafter acquired, in, to and
under all of the Collateral.

    


    NOW, THEREFORE, for good and valuable
consideration, receipt of which is hereby acknowledged, and intending to be
legally bound, as collateral security for the prompt and complete payment when
due of its obligations under the Loan Agreement, Grantor hereby represents,
warrants, covenants and agrees as follows:

    


    AGREEMENT

    


    To secure its obligations under the
Loan Agreement, Grantor grants and pledges to Agent, for the ratable benefit of
the Lenders, a security interest in all of Grantor's right, title and interest
in, to and under its intellectual property (all of which shall collectively be
called the "Intellectual Property Collateral"), including, without limitation,
the following:

    


    (a)           Any
and all copyright rights, copyright applications, copyright registrations and
like protections in each work or authorship and derivative work thereof, whether
published or unpublished and whether or not the same also constitutes a trade
secret, now or hereafter existing, created, acquired or held, including without
limitation those set forth on Exhibit A attached
hereto (collectively, the "Copyrights");

    


    (b)           Any
and all trade secrets, and any and all intellectual property rights in computer
software and computer software products now or hereafter existing, created,
acquired or held;

    


    (c)           Any
and all design rights that may be available to Grantor now or hereafter
existing, created, acquired or held;

    


    (d)           All
patents, patent applications and like protections including, without limitation,
improvements, divisions, continuations, renewals, reissues, extensions and
continuations-in-part of the same, including without limitation the patents and
patent applications set forth on Exhibit B attached
hereto (collectively, the "Patents");

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (e)           Any
trademark and servicemark rights, whether registered or not, applications to
register and registrations of the same and like protections, and the entire
goodwill of the business of Grantor connected with and symbolized by such
trademarks, including without limitation those set forth on Exhibit C attached
hereto (collectively, the "Trademarks");

    


    (f)           All
mask works or similar rights available for the protection of semiconductor
chips, now owned or hereafter acquired, including, without limitation those set
forth on Exhibit
D attached hereto (collectively, the  “Mask
Works”);

    


    (g)           Any
and all claims for damages by way of past, present and future infringements of
any of the rights included above, with the right, but not the obligation, to sue
for and collect such damages for said use or infringement of the intellectual
property rights identified above;

    


    (h)           All
licenses or other rights to use any of the Copyrights, Patents, Trademarks, or
Mask Works and all license fees and royalties arising from such use to the
extent permitted by such license or rights;

    


    (i)           All
amendments, extensions, renewals and extensions of any of the Copyrights,
Trademarks, Patents, or Mask Works; and

    


    (j)           All
proceeds and products of the foregoing, including without limitation all
payments under insurance or any indemnity or warranty payable in respect of any
of the foregoing.

    


    This security interest is granted in
conjunction with the security interest granted to Agent, for the ratable benefit
of the Lenders, under the Loan Agreement.  The rights and remedies of
Agent with respect to the security interest granted hereby are in addition to
those set forth in the Loan Agreement and the other Loan Documents, and those
which are now or hereafter available to Agent as a matter of law or
equity.  Each right, power and remedy of Agent provided for herein or
in the Loan Agreement or any of the Loan Documents, or now or hereafter existing
at law or in equity shall be cumulative and concurrent and shall be in addition
to every right, power or remedy provided for herein and the exercise by Agent of
any one or more of the rights, powers or remedies provided for in this
Intellectual Property Security Agreement, the Loan Agreement or any of the other
Loan Documents, or now or hereafter existing at law or in equity, shall not
preclude the simultaneous or later exercise by any person, including Agent, of
any or all other rights, powers or remedies.

    


    [Signature
page follows.]

     

    
      
         


      

      
        2

        
          

        

      

      
         


      

    


    IN WITNESS WHEREOF, the parties have
caused this Intellectual Property Security Agreement to be duly executed by its
officers thereunto duly authorized as of the first date written
above.

    


     

    
      	 	 	
              GRANTOR:

               

            
	Address of
      Grantor:	 	PEREGRINE
      PHARMACEUTICALS, INC.
	 	 	 
	14282 Franklin
      Avenue	 	By: /s/ Steven King 
	Tustin,
      California 92780 

              Attn:
      Paul Lytle

            	 	
               

              Title:
      President and
      CEO   

            
	 	 	 
	 	 	
              AGENT:

               

            
	Address
      of Agent:	 	MIDCAP
      FUNDING I, LLC
	 	 	 
	7735 Old Georgetown
      Road, Suite 400	 	By: /s/ Joshua Groman 
	Bethesda,
      Maryland 20814 

              Attn:
      Portfolio Management- Life Sciences

            	 	
               

              Title:
      Managing
      Director     

            


    

     

    
      
         


      

      
        3

        
          

        

      

      
         


      

    


    EXHIBIT
A

    


    Copyrights

    


    


    
      	
              Description

            	
              Registration/

              Application

              Number

            	
              Registration/

              Application

              Date

            
	 
      	 
      	 
      
	
              NONE

            	
              N/A

            	
              N/A

            


    


    
      
         


      

      
        4

        
          

        

      

      
         


      

    


    EXHIBIT
B

    


    Patents

    


    


    
      	
              Description

            	
              Registration/

              Application

              Number

            	
              Registration/

              Application

              Date

            
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              6,827,925

            	
              12/07/2004

            
	 	 	 
	
              COMPOSITION
      AND METHOD FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS RESULTING IN
      CHRONIC CONDITIONS

            	
              6,255,291

            	
              07/03/2001

            
	 	 	 
	
              DETECTION
      OF NECROTIC MALIGNANT TISSUE AND ASSOCIATED THERAPY

            	
              6,071,491

            	
              06/06/2000

            
	 	 	 
	
              DETECTION
      OF NECROTIC MALIGNANT TISSUE AND ASSOCIATED THERAPY

            	
              6,017,514

            	
              01/25/2000

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              5,990,286

            	
              11/23/1999

            
	 	 	 
	
              DETECTION
      OF NECROTIC MALIGNANT TISSUE AND ASSOCIATED THERAPY

            	
              5,882,626

            	
              03/16/1999

            
	 	 	 
	
              METHOD
      OF DIAGNOSING BY DETERMINING FORMIC ACID TO NICOTINIC ACID
      RATIO

            	
              5,879,880

            	
              04/25/1997

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              5,194,594

            	
              03/16/1993

            
	 	 	 
	
              DETECTION
      OF NECROTIC MALIGNANT TISSUE AND ASSOCIATED THERAPY

            	
              5,019,368

            	
              05/28/1991

            
	 	 	 
	
              CONSTRUCTS
      BINDING TO PHOSPHATIDYLSERINE AND THEIR USE IN DISEASE
      TREATMENT

            	
              11/339,392

            	
              01/24/2006

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              10/890,945

            	
              07/13/2004

            
	 	 	 
	
              METHODS
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              10/877,959

            	
              06/25/2004

            
	 	 	 
	
              COMBINED
      COMPOSITIONS FOR TUMOR VASCULATURE COAGULATION AND TREATMENT
      (Abandoned)

            	
              10/259,244

            	
              09/27/2002

            


    

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    
      	
              COMBINED
      METHODS FOR TUMOR VASCULATURE COAGULATION AND TREATMENT
      (Abandoned)

            	
              10/259,236

            	
              09/27/2002

            
	 	 	 
	
              COMBINED
      METHODS FOR TUMOR VASCULATURE COAGULIGAND TREATMENT
      (Abandoned)

            	
              10/259,227

            	
              09/27/2002

            
	 	 	 
	
              COMBINED
      COMPOSITIONS FOR TUMOR VASCULATURE COAGULIGAND TREATMENT
      (Abandoned)

            	
              10/259,223

            	
              09/27/2002

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              PCT/US06/002964

            	
              01/24/2006

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              AU
      2006206187

            	
              08/01/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              CA
      2,591,914

            	
              06/20/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              CN
      200680007064.8

            	
              09/04/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              EP
      06719706.1

            	
              08/22/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              IL
      184406

            	
              07/04/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              IN
      5739/DELNP/2007

            	
              07/24/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              JP
      2007-552418

            	
              07/23/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              NZ
      556065

            	
              06/22/2007

            
	 	 	 
	
              Fc
      FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC
      USE

            	
              SG
      200704601-4

            	
              06/20/2007

            


    

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    
      	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              PCT/US04/020492

            	
              06/25/2004

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              AU
      2004253924

            	
              11/25/2005

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              BE
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              CA
      2,527,054

            	
              11/24/2005

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              CH
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              CN
      200480017742.X

            	
              12/23/2005

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              DE
      60 2004 015 454

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              DN
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              EP
      2004785799

            	
              01/09/2006

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              EP
      08010871.5

            	
              06/13/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              FI
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              FR
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              GB
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              HK
      06109573.0

            	
              08/28/2006

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              IE
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              IN
      419/DELNP/2006

            	
              01/23/2006

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              NL
      1 638 989

            	
              07/30/2008

            


    

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    
      	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              NZ
      543495

            	
              11/10/2005

            
	 	 	 
	
              METHOD
      AND APPARATUS FOR CONTINUOUS LARGE-SCALE RADIOLABELING OF
      PROTEINS

            	
              SE
      1 638 989

            	
              07/30/2008

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              PCT/EP02/010913

            	
              09/27/2002

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              AU
      2002362487

            	
              03/03/2004

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              CA
      2461905

            	
              03/26/2004

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              EP
      02800138.6

            	
              04/23/2004

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              HK
      02800138.6

            	
              10/05/2004

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              NZ
      532539

            	
              04/26/2004

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              MC
      0 627 940

            	
              05/07/2003

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              NL
      0 627 940

            	
              05/07/2003

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              PT
      0 627 940

            	
              05/07/2003

            
	 	 	 
	
              COMBINED
      COMPOSITIONS AND METHODS FOR TUMOR VASCULATURE COAGULATION AND
      TREATMENT

            	
              SE
      0 627 940

            	
              05/07/2003

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              AU
      766564

            	
              07/02/1999

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              CA
      2,336,114

            	
              07/02/1999

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              EP
      1 092 028

            	
              07/02/1999

            


    

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    
      	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              DN
      1 092 028

            	
              07/02/1999

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              FR
      1 092 028

            	
              07/02/1999

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              GB
      1 092 028

            	
              07/02/1999

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              NL
      1 092 028

            	
              07/02/1999

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              JP
      2000-558212

            	
              07/02/1999

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF

            	
              EP
      0510644.2

            	
              05/17/2005

            
	 	 	 
	
              SPECIFIC
      BINDING PROTEINS INCLUDING ANTIBODIES WHICH BIND TO THE NECROTIC CENTRE OF
      TUMOURS, AND USES THEREOF (HONG KONG)

            	
              HK
      06108478.8

            	
              7/2/1999

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              EP
      0 550 663

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              DN
      0 550 663

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              FR
      0 550 663

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              GB
      0 550 663

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              IT
      0 550 663

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              CH
      0 550 663

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              CA
      2,090,700

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              JP
      3549525

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              JP
      2004-13610

            	
              08/28/1991

            
	 	 	 
	
              MODIFIED
      ANTIBODIES

            	
              AU
      649079

            	
              08/28/1991

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              EP
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              AU
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              CH
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              DN
      0 873 139

            	
              01/06/1997

            


    

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    
      	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              ES
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              FR
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              GB
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              IT
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              RU
      0 873 139

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              AU
      730388

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              CA
      2242750

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              JP
      525384/1997

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              KR
      485240

            	
              01/06/1997

            
	 	 	 
	
              ANTIBODIES
      WITH REDUCED NET POSITIVE CHARGE

            	
              MX
      985565

            	
              01/06/1997

            


    


    
      
         


      

      
        10

        
          

        

      

      
         


      

    


    EXHIBIT
C

    


    Trademarks

    


    


    
      	
              Description

            	
              Registration/

              Application

              Number

            	
              Registration/

              Application

              Date

            
	
              AVID
      BIOSERVICES, INC. (Registered)

            	
              3,362,424

            	
              01/01/2008

            
	
              AVID
      BIOSERVICES (Registered)

            	
              3,348,388

            	
              12/04/2007

            
	
              COTARA
      (Registered)

            	
              2,817,648

            	
              02/24/2004

            


    


    
      
         


      

      
        11

        
          

        

      

      
         


      

    


    EXHIBIT
D

    


    Mask
Works

    


    


    
      	
              Description

            	
              Registration/

              Application

              Number

            	
              Registration/

              Application

              Date

            
	 
      	 
      	 
      


    

     

    12